

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Vincent Medical Holdings Limited**

**永勝醫療控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

(Stock code: 1612)

### **PROFIT WARNING**

This announcement is made by Vincent Medical Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the “**Board**”) of directors (the “**Directors**”) of the Company wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that based on the latest review of the Group’s unaudited consolidated management accounts for the six months ended 30 June 2017 (“**1H2017**”) and information currently available to the Company, the Group is expected to record a significant decrease of about 60% in the profit attributable to owners of the Company for 1H2017 as compared that for the six months ended 30 June 2016 (“**1H2016**”) (without taking into account the one-off listing-related expenses (the “**Listing Expenses**”) of approximately HK\$17.1 million).

The Board considers that the significant decline in the net profit is mainly attributable to:

- (i) the decrease in revenue of about 15% mainly as a result of the drop in orders from two major customers of the Group’s original equipment manufacturing business; and
- (ii) the increase in administrative expenses of approximately HK\$13 million (without taking into account the Listing Expenses in 1H2016), mainly due to the increase in (a) research and development expenses mainly as a result of certain new research projects on the Group’s original brand manufacturing products; (b) staff costs mainly as a result of the increase in headcount and salary increment; (c) professional and compliance fees mainly arising from merger and acquisitions; (d) exchange loss mainly as a result of the appreciation of Renminbi; and (e) share-based compensation expenses relating to the pre-IPO share options.

The Company is still in the process of finalising the interim results of the Group for 1H2017. The information contained in this announcement is only based on a preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group for 1H2017 and the unaudited information currently available to the Company, which have not been confirmed or reviewed by the Company's auditors. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for 1H2017 which will be published before the end of August 2017 pursuant to the requirements of the Listing Rules.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Vincent Medical Holdings Limited**  
**Choi Man Shing**  
*Chairman and Executive Director*

Hong Kong, 28 July 2017

*As at the date of this announcement, the Board comprises Mr. Choi Man Shing, Mr. To Ki Cheung, Mr. Koh Ming Fai and Mr. Fu Kwok Fu as executive Directors, Ms. Liu Pui Ching and Mr. Guo Pengcheng as non-executive Directors, and Mr. Chan Ling Ming, Mr. Mok Kwok Cheung Rupert, Mr. Au Yu Chiu Steven and Prof. Yung Kai Leung as independent non-executive Directors.*